Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus carboplatin-etoposide first-line treatment for advanced or metastatic pulmonary LCNEC
ChiCTR2300068111Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab, carboplatin and etoposide in large cell neuroendocrine carcinoma (LCNEC), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
serplulimabcarboplatinetoposide
03
Conditions
large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on ChiCTR2300068111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068111.